The tyrosine kinase inhibitor (TKI) imatinib produces mast cell deficiency in Ph plus chronic myeloid leukemia

被引：0
|
作者：
Cerny-Reiterer, S. [1 ,2 ]
Herndlhofer, S. [2 ]
Stefanzl, G. [2 ]
Blatt, K. [2 ]
Hoermann, G. [3 ]
Muellauer, L. [4 ]
Beham-Schmid, C. [5 ]
Baumgartner, S. [6 ]
Sperr, W. S. R. [2 ]
Mannhalter, C. [3 ]
Linkesch, W. [7 ]
Valent, P. [1 ,2 ]
机构：
[1] Ludwig Boltzmann Cluster Oncol, Vienna, Austria
[2] Med Univ Vienna, Dept Internal Med 1, Div Hematol & Hemostaseol, Vienna, Austria
[3] Med Univ Vienna, Dept Lab Med, Vienna, Austria
[4] Med Univ Vienna, Dept Pathol, Vienna, Austria
[5] Med Univ Graz, Inst Pathol, Graz, Austria
[6] Med Univ Vienna, Dept Pediat & Adolescent Med, Vienna, Austria
[7] Med Univ Graz, Dept Internal Med, Div Haematol, Graz, Austria
来源：
ONKOLOGIE | 2013年 / 36卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：63 / 63
页数：1
相关论文
共 50 条
  • [31] Impact of Tyrosine Kinase Inhibitor (TKI) in Chronic Myeloid Leukemia (CML) Relapsing After T Cell Depleted Allogeneic Stem Cell Transplantation (SCT)
    Ito, Sawa
    Battiwalla, Minoo
    Koklanaris, Eleftheria K.
    Superata, Jeanine
    Childs, Richard
    Barrett, John
    BLOOD, 2011, 118 (21) : 1188 - 1189
  • [32] Treatment Responses in Patients with Chronic Myeloid Leukemia on Tyrosine Kinase Inhibitors (TKI) Therapy
    Mir, Ahmed Ali
    Mir, Abdur Rehman
    Rehmat, Uswah
    Shakoor, Ifra
    Amjad, Farhan
    Khalid, Muhammad
    Mallhi, Tauqeer Hussain
    Laique, Talha
    PAKISTAN JOURNAL OF MEDICAL & HEALTH SCIENCES, 2021, 15 (09): : 2358 - 2360
  • [33] Outcomes of blast phase chronic myeloid leukemia (BP-CML) in the tyrosine kinase inhibitor (TKI) era.
    Talati, Chetasi
    Isenalumhe, Leidy Lismeri
    Shams, Samantha Reiter
    Kuykendall, Andrew Tucker
    Chavez, Julio C.
    Shah, Bijal D.
    Sweet, Kendra Lynn
    Pinilla-Ibarz, Javier
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [34] Fine-tuning of frontline tyrosine kinase inhibitor (TKI) therapy in chronic-phase chronic myeloid leukemia: The choice of the right TKI for the right patient
    Kantarci, Eda Nuhoglu
    Tolgay, Ece
    Eskazan, Ahmet Emre
    CANCER, 2023, 129 (17) : 2610 - 2612
  • [35] Adherence to oral tyrosine kinase inhibitor therapies in chronic myeloid leukemia
    Gater, Adam
    Heron, Louise
    Abetz-Webb, Linda
    Coombs, John
    Simmons, Jeff
    Guilhot, Francois
    Rea, Delphine
    LEUKEMIA RESEARCH, 2012, 36 (07) : 817 - 825
  • [36] Chronic Myeloid Leukemia-the Promise of Tyrosine Kinase Inhibitor Discontinuation
    Narra, Ravi Kishore
    Flynn, Kathryn E.
    Atallah, Ehab
    CURRENT HEMATOLOGIC MALIGNANCY REPORTS, 2017, 12 (05) : 415 - 423
  • [37] Dose optimization of tyrosine kinase inhibitor therapy in chronic myeloid leukemia
    Umezawa, Yoshihiro
    Sasaki, Koji
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2023, 117 (01) : 24 - 29
  • [38] Tyrosine kinase inhibitor associated vascular toxicity in chronic myeloid leukemia
    Pasvolsky O.
    Leader A.
    Iakobishvili Z.
    Wasserstrum Y.
    Kornowski R.
    Raanani P.
    Cardio-Oncology, 1 (1)
  • [39] Tyrosine Kinase Inhibitor Treatment for Newly Diagnosed Chronic Myeloid Leukemia
    Radich, Jerald P.
    Mauro, Michael J.
    HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2017, 31 (04) : 577 - +
  • [40] Aortic Stenosis and the Tyrosine Kinase Inhibitor Nilotinib in Chronic Myeloid Leukemia
    Carracedo, Miguel
    Stenke, Leif
    Franco-Cereceda, Anders
    Back, Magnus
    JACC: CARDIOONCOLOGY, 2020, 2 (01): : 123 - 126
12345